Table 1.
Results of clinical trials of pemetrexed.
| Trial | Phase | Line | Type | n | RR(CR/PR) | DCR(CR/PR/SD) | Time to Progression | PFS | MST or OS |
|---|---|---|---|---|---|---|---|---|---|
| Scagliotti G.V. 2003 PEM alone |
II | 1st line | MPM | 64 | 14.1% | 65.6% | 4.7 m | 10.7 m | |
| Vogelzang N.J. 2003 PEM/CDDP vs. CDDP |
III | 1st line | MPM | 456 | 41.3% vs. 16.7% | 5.7 m vs. 3.9 m | 12.1 m vs. 9.3 m | ||
| Hughes A. 2002 PEM/CBDCA |
I | 1st line | MPM | 27 | 32% | 88% | 305 d | 451 d | |
| Ceresoli G.L. 2006 PEM/CBDCA |
II | 1st line | MPM | 102 | 18.6% | 65.7% | 6.5 m | 12.7 m | |
| Castagneto B. 2008 PEM/CBDCA |
II | 1st line | MPM | 76 | 25% | 63% | 8 m | 14.1 m | |
| Hanna N. 2004 PEM vs. DTX |
III | 2nd line | NSCLC | 571 | 9.1% vs. 8.8% | 3.4 m vs. 3.5 m | 2.9 m vs. 2.9 m | 8.3 m vs. 7.9 m | |
| Scagliotti G.V. 2008 CDDP/PEM vs. CDDP/GEM (JMDB trial) |
III | 1st line | NSCLC | 1725 | 30.6% vs. 28.2% | 4.8 m vs. 5.1 m | 10.3 m vs. 10.3 m | ||
| Non Sq | 1000 | 5.3 m vs. 4.7 m | 11.8 m vs. 10.4 m | ||||||
| Sq | 473 | 4.4 m vs. 5.5 m | 9.4 m vs. 10.8 m | ||||||
| Paz-Ares L.G. 2013 PEM maintenance vs. placebo (PARAMOUNT trial) |
III | Induction | NSCLC | 939 | 4.4 m vs. 2.8 m | 13.9 m vs. 11.0 m | |||
| Gandhi L. 2018 Platinum/PEM/ Pembrolizumab vs. Platinum/PEM/ placebo |
III | 1st line | NSCLC | 616 | 47.6% vs. 18.9% | 84.6% vs. 70.4% | 8.8 m vs. 4.9 m | Not reachedvs 11.3 m |
MPM: malignant pleural mesothelioma, NSCLC: non-small cell lung cancer, NonSq: nonsquamous cell carcinoma, RR: response rate, CR: complete response, PR: partial response, DCR: disease control rate, SD: stable disease, PFS: progression free survival, MST: medial survival time, OS: overall survival, PEM: pemetrexed, CDDP: cisplatin, CBDCA: carboplatin, DTX: docetaxel, GEM: gemcitabine.